Skip to content
Screener

MiMedx Group MDXG Q3 2026 earnings

Reported October 28, 2026 · After market close

Revenue$62.3MMiss by $6.3M
EPS-$0.01Miss by $0.01
Revenue estimate$68.6M
EPS estimate$0.00

Next report

Date not yet announced

Financials

Q3 2026

Income statement

See full
Revenue$62.3M-45.2%
Gross profit$49.7M-47.7%
Operating income-$11.7M-153%
Net income-$8.7M-152%
EPS (diluted)-$0.06-155%

Balance sheet

See full
Cash & equivalents$120.8M-15.0%
Total equity$211.1M-11.7%
Total assets$264.6M-17.1%

Cash flow

See full
CapEx$166.0K-13.5%

Valuation & ratios

Valuation

as of 10/30/26
See full
Market cap$579.32M-47.1%
P/S1.9×-0.9×

Profitability

See full
Gross margin77.3%-4.7pp
Operating margin-8.3%-22.0pp
Net margin-6.3%-16.7pp

Returns & leverage

See full
Return on equity-8.5%-28.0pp
Current ratio4.4×-0.1×

Segments

By product

See full
Surgical$40.0M+9.1%
Wound$22.3M-71.0%

FAQ

When did MiMedx Group report Q3 2026 earnings?
MiMedx Group (MDXG) reported Q3 2026 earnings on October 28, 2026 after market close.
What were MiMedx Group's Q3 2026 revenue and EPS?
MiMedx Group reported revenue of $62.3M and eps of $-0.01 for Q3 2026.
Did MiMedx Group beat estimates in Q3 2026?
Revenue missed the consensus estimate of $68.6M by $6.3M. EPS missed the consensus estimate of $0.00 by $0.01.
How did MiMedx Group's Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 45.2% from $113.7M a year earlier.
Where can I find MiMedx Group's Q3 2026 SEC filings?
You can read the 8-K earnings release (0001376339-26-000094) and the 10-Q periodic report (0001376339-26-000093) directly on SEC EDGAR. The filing index links above go to sec.gov.